Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems-Trading Strong Earnings Growth and Momentum -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (4545)	2/14/2001 8:55:16 AM
From: Jenna	Read Replies (2) \| Respond to of 6445

PRESS RELEASE:Immunomedics Gets Positron Emission Patent U.S. Patent on Positron Emission Tomography Agents Awarded to Immunomedics MORRIS PLAINS, N.J., Feb. 14 /PRNewswire/ -- Immunomedics, Inc. (Nasdaq: IMMU) today announced that U.S. patent 6,187,284 issued yesterday to the Company. This patent covers the fluorination of proteins and peptides for F-18 positron emission tomography (PET). "PET is the most exciting new diagnostic imaging technology being used by nuclear physicians," commented Cynthia L. Sullivan, President and Chief Operating Officer of Immunomedics. "Virtually all PET currently uses fluorine-18 conjugated to deoxyglucose, which is taken up by rapidly growing cells, such as various tumors, but is not specific for cancer. Our goal has been to develop more specific, next-generation, PET imaging agents for cancer, and this patent is the second in a series protecting our inventions," she added. Ms. Sullivan explained: "This patent involves the attachment of F-18 to thiol-containing peptides, and these peptides can be selected from antibodies and antibody fragment constructs that target specific diseased tissues, including cancers." "Our prior patent in this field, issued in 2000, included the use of a gallium PET isotope also attached to targeting proteins and haptens, thus providing various product options." "Although we are now focusing our resources on cancer therapeutics, these patents expand the intellectual property of our diagnostic imaging business, which we anticipate will increase its overall value to potential licensing partners," she clarified. Immunomedics is a biopharmaceutical company focused on the development, manufacture and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer and infectious diseases. Integral to these products are highly specific monoclonal antibodies and antibody fragments designed to deliver radioisotopes and chemotherapeutic agents to tumors and sites of infection. Immunomedics has three therapeutic products in clinical trials and has two marketed diagnostic imaging products. The most advanced therapeutic products are LymphoCide(TM) (epratuzumab), which has begun Phase III clinical trials for the treatment of non-Hodgkin's lymphoma, and CEA-Cide(TM), which is in Phase I/II clinical trials for the treatment of certain solid tumors. This release, in addition to historical information, contains forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including the statements regarding future clinical trials, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), competitive risks to marketed products and availability of financing and other sources of capital, as well as the risks discussed in the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2000. SOURCE Immunomedics, Inc.